Skip to content

TITLE: Pediatric Pancreatitis Patient and Family Input Study

Title: Diabetes RElated to Acute pancreatitis and its Mechanisms (DREAM)
This research study is being conducted by the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC) which is funded by the National Institute of Diabetes and Digestive and Kidney Diseases. The DREAM study will enroll adult participants between the ages of 18 and 75 years old who have been recently diagnosed with acute pancreatitis. Participants with or without a diagnosis of diabetes may be eligible to participate. The purpose of this study is to find out if having acute pancreatitis increases your risk for diabetes. Eligible participants will receive compensation for completing study visits.
To learn more about the DREAM study and to find participating clinical centers within the United States, please visit the T1DAPC website at

You are invited to take part in a research study survey. The goal of the study is to look for ways to improve the quality of life of children who have pancreatitis and their families. We want to know how pancreatitis affects your child’s body, how they feel, your family, friends, school, and activities. We want to know which areas you would like us to study and in which areas you would like help to improve. If you agree to take part in this study, you will complete a one-time 15-minute survey. This study is being conducted by the University of Iowa Department of Pediatrics. The research will take place wherever you decide to complete the survey.

If you have any questions about the research study itself, please contact Gretchen Cress, (319) 353-4544. You may be eligible for this study if you are the parent of a child who has pancreatitis, a child who has pancreatitis or the brother or sister of a child with pancreatitis. Participants will be asked to enter their age and relationship to the person who has pancreatitis into the survey to determine their eligibility. Any child taking the survey must be at least 10 years old. A parent must give permission for children 10-17 years old to participate in this study.

There are no benefits to participating in this study. If interested, please click on this link:

Title: WEBMAP CP  STUDY (Pediatric Pancreatitis)

This research study is for children with pain from chronic pancreatitis

Researchers at Seattle Children’s Hospital want to learn more about pain management strategies to help youth with pancreatitis! Children ages 10-18 and their parents can earn up to $300 for their time. Study participation is completely online.

Go to to learn more!

Teens who participate in this study will:

• Answer questions about your pain,
mood, sleep, and everyday life at 3
times over 9 months.
• Use a website for 8-12 weeks, to
learn pain coping skills, which might
help with managing pain

To participate in this study or learn more, please fill out the form located at  If you or a family member have questions about the study, please contact Seattle Children’s staff at 1-855-932-6272 (toll-free) or

TITLE: Chronic Pancreatitis Trial – Kangen Pharmaceuticals.  A Phase 2, randomized, DOUBLE-BLIND, PARALLEL‑GROUP dose-ranging STUDY TO EVALUATE THE Safety and efficacy OF Ni-03 compared to placebo in subjects with chronic pancreatitis.

A multicenter, randomized, double-blind, placebo-controlled study of three doses of NI-03. The aim of the study is to evaluate if the study drug is effective in treating the acute symptoms of chronic pancreatitis when given for 4 weeks. The study is currently enrolling patients nationwide.

If you or someone you love is 18 years of age or older and diagnosed with Chronic Pancreatitis, you may qualify for a clinical trial. Please CLICK HERE to visit the TACTIC study website to answer a few simple questions about your Chronic Pancreatitis and locate a site nearest you. Eligible participants will receive study-related treatment at no charge, and will also receive compensation for their time and travel.

TITLE: Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)

This research study—called the DETECT* Study – is funded by the National Institutes of Health (NIH) and is seeking to develop a blood test that can separate diabetes caused by pancreatic cancer or chronic pancreatitis from type 2 diabetes.

The study includes participants from 8 research centers in the United States.  If you have pancreatic cancer or chronic pancreatitis, and have also been diagnosed with diabetes, and are 40 to 85 years old, you may be eligible after review of other factors.  For more information, please CLICK HERE

TITLE: SpHincterotomy for Acute Recurrent Pancreatitis (SHARP)

This NIH-sponsored Randomized Clinical Trial is currently enrolling subjects to learn whether an Endoscopic Retrograde CholangioPancreatography (ERCP) with sphincterotomy is beneficial in patients with acute recurrent pancreatitis and pancreas divisum.

The purpose of this study is to determine if a ERCP with sphincterotomy reduces the risk of pancreatitis or the number of recurrent pancreatitis episodes in patients with pancreas divisum. ERCP with sphincterotomy is a procedure where doctors used a combination of x-rays and an endoscope (a long flexible lighted tube) to find the opening of the duct where fluid drains out of the pancreas. People who have been diagnosed with pancreas divisum, have had at least two episodes of pancreatitis, and are candidates for the ERCP with sphincterotomy procedure may be eligible to participate. Participants will be will be randomly assigned to either have the ERCP with sphincterotomy procedure, or to have a “sham” procedure. Participants will have follow up visits 30 days after the procedure, 6 months after the procedure, and continuing every 6 months until a maximum follow-up period of 48 months.

For more information please go here:
There are currently several sites ready to enroll patients across the nation. For more information about the study and contact on sites is available here:

If you are interested in participating, please call (843) 876-4261

Title: Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

The primary objective of the study is to determine the proportion of patients with triglycerides (TG) >880 mg/dL, without familial chylomicronemia syndrome (FCS) due to loss of function (LoF) mutations in lipoprotein lipase (LPL), and a history of hypertriglyceridemia (HTG)-associated acute pancreatitis (AP) who experience a recurrent episode of AP after treatment with evinacumab versus placebo.

For more information, please CLICK HERE.

Oregon Health & Science University Brenden-Colson Center – Multiple Trials Available